Expert Video - How is higher-risk MDS-related anemia treated?
MDS experts, Dr Rafael Bejar and Dr Casey O’Connell describe how higher-risk MDS-related anemia is treated. They discuss the use of hypomethylating agents (HMAs), such as azacitidine and decitabine, for higher risk MDS. These therapies are effective at improving low blood cell counts in about fifty percent of patients. They also explain how patients might be assessed as candidates for a stem cell transplant.
Share with family and friends:
Click here to take our SURVEY Your feedback is important to us! We will use your feedback to develop future areas of content about MDS which will help other patients, caregivers and families.
This educational activity has been developed by the Myelodysplastic Syndromes Foundation, Inc. and Mechanisms in Medicine Inc.
This activity is supported by an educational grant from Acceleron Pharma, Celgene Corporation, Jazz Pharmaceuticals, Novartis, and Takeda Oncology.
This website is part of the Animated Patient™ series developed by Mechanisms in Medicine Inc., to provide highly visual formats of learning for patients to improve their understanding, make informed decisions, and partner with their healthcare professionals for optimal outcomes.